Study #2024-0515
A Phase 2 study evaluating Olutasidenib in combination with hypomethylating agents in patients with IDH1-mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms
MD Anderson Study Status
Enrolling
Treatment Agent
Olutasidenib
Description
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes
Study phase:
Phase II
Physician name:
Kelly Chien
Department:
Leukemia
For general questions about clinical trials:
1-855-625-0962
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.